GlobeNewswire by notified

Palette Life Sciences Announces Completion of $30 Million Equity Financing and Expansion of the Board of Directors

Share

-Funds will be used for expansion of commercial US footprint and acceleration of clinical development of Barrigel®-

SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, a Swedish domiciled, fully integrated global life sciences company dedicated to improving patient outcomes, announced today that the company has completed a $30 million equity financing during the spring and also expanded its Board of Directors by five members.

“This capital raise allows for Palette Life Sciences’ to continue to expand our commercial presence in the United States and other key markets and bring products like Barrigel® to the global marketplace,” said Per G. Langö, Chief Executive Officer and Board Director of Palette Life Sciences. “We are excited to strengthen our team with the appointment of exceptional leaders. Each will provide significant expertise in their respective functions as we expand our product portfolio and deliver best in class care to our patients worldwide.”

The investment was led by the Swedish privately held investment firm Melker Schörling AB and a global player in the Oncology space. Carnegie Investment Bank acted as financial advisor of the capital raise which was completed earlier this year. Back Bay Life Science Advisors has acted as strategic advisor to Palette Life Sciences.

With the addition of the new members the Palette Life Sciences’ Board of Directors now consists of eight members bringing vast operational expertise to the company through their advisory roles.

New members of the Palette Life Sciences’ Board of Directors include the following:

  • Dave R. Amerson (Chairman) is a former Chief Executive Officer of NeoTract and former president of the Teleflex Urology franchise. He currently serves as Chairman of NC8, a ExploraMed company. Mr. Amerson also serves as a board member of Calyxo Medical. In addition, he was global vice president and general manager of Coloplast’s Surgical Urology Division and global vice president of sales and marketing for Mentor’s urology division.

  • Newton Aguiar is an independent investor and advisor. Mr. Aguiar is a former managing director at Credit Suisse London office. Previous roles include senior health care advisor at Warburg Pincus LLC and a partner at Avista Capital Partners. Mr. Aguiar has been involved with several successful health care investments and in addition to Palette Life Sciences, he currently sits on the board of OssDsign AB.

  • Ted Lamson, PhD is co-founder of NeoTract and co-inventor of UroLift for enlarged prostates. He served as Chief Technical Officer for Clinical and Medical Affairs in Teleflex. He is a Strategic Advisor to ExploraMed and serves on the board of Eximis Surgical and advisor to Calyxo. Dr. Lamson has also held management roles in Medtronic and Pfizer.

  • Sam Navarro is the managing partner and founder of Gravitas Healthcare LLC. Among his previous roles, he was senior portfolio manager of the Galleon Group Healthcare Fund, and Global head of Healthcare Investment Banking at ING Barings. Mr. Navarro is also on the Board of Directors of BioSig Technologies.

  • Gun Nilsson is CEO of Melker Schorling AB, and former Chief Executive Officer of Gambro Holding AB. Ms. Nilsson also serves as Chairman of the Board of Hexagon AB, and a member of the boards of AAK, Absolent, Hexpol, Bonnier Group AG, Loomis AB and Einar Mattsson. Ms. Nilsson is also Chairman of Swedish Corporate Governance Board and has vast operational experience from several public companies.

The new members will join Palette Life Sciences’ current Directors:

  • Per Langö is the Chief Executive Officer and Board Director of Palette Life Sciences. Prior to his current role Mr. Langö was Head of M&A at Nestle Skin Health and vice president of marketing for Galderma’s US aesthetic franchise. Previous roles include vice president of Global marketing for Galderma and various leadership roles at Q-Med AB and Pharmacia Corporation

  • Mattias Klintemar is an investment director of Östersjöstiftelsen, an evergreen Swedish Investment group. Mr. Klintemar serves on a number of boards including Oatly and Moberg Pharma.

  • Paul De Potocki is a former president and Chief Executive Officer of public companies Diagenic and Aerocrine. He currently serves as Chairman of the Board of Asarina Pharma and is a former board member of Athera Biotechnologies. Mr. De Potocki has also served as global vice president of commercial operations at Biovitrum, FreseniusKabi and Pharmacia & Upjohn.

About Palette Life Sciences

Palette Life Sciences is a fully integrated life sciences company. Palette Life Sciences’ products improve patient outcomes in urology and urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. The company’s portfolio of available products includes Deflux®, Barrigel®, Solesta®, and Lidbree™. Palette Life Sciences moves rapidly to leverage novel applications of existing technologies to create breakthrough medical solutions. This focus enables the company to serve those often overlooked by traditional medical companies and improve patient quality of life. Led by experienced healthcare executives, Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California, Dallas, Texas, and Sydney, Australia. Learn more at http://www.palettelifesciences.com.

Media Contact

Erich Sandoval
Lazar-FINN Partners
Erich.sandoval@finnpartners.com
(917) 497-2867

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC28.3.2024 19:00:00 CET | Press release

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 28, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on March 27, 2024, from Atlas Special Opportunities, LLC indicating that as of March 19, 2024, it held 0 (zero) shares of the then outstanding 5,753,951,723 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. About Oxurion Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com. Important information about forward-looking statements Certain statements in this press rele

C.K. McWhorter: Running to a Solution Of Equality and Sustainability28.3.2024 18:48:29 CET | Press release

MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- In a groundbreaking endeavor, C.K. McWhorter, renowned for his pioneering spirit in luxury and finance, is embarking on a transformative journey to reshape the narrative of desirability. By harnessing the allure of luxury, McWhorter aims to catalyze a paradigm shift towards equality and sustainability, ensuring that these principles become the most coveted and revered ideals worldwide. With a profound understanding of the power of influence, McWhorter recognizes that luxury sets the standard for aspiration and desire. Leveraging this influence, he seeks to redefine what it means to truly desire and value, shifting the focus from just material possessions to ethical principles that benefit humanity and the planet. "Luxury has long been synonymous with opulence and exclusivity, but it's time for us to redefine its meaning," says McWhorter. "True luxury is in equality and sustainability – in knowing that our desires are aligned with values that up

Multitude Group Annual Report 2023 published - on track for substantial profitable growth in 2024 and beyond28.3.2024 18:30:00 CET | Press release

Multitude Group Annual Report 2023 published - on track for substantial profitable growth in 2024 and beyond Guidance for 2023 achieved: EBIT plus 44.8% to EUR 45.6 million Revenue up 8.5 % to EUR 230.5 millionNet profit jumped to EUR 16.4 million, basic earnings per share amount to EUR 0.51 Loans to customers and debt investments increased by 20.8% to EUR 638.1 million, impaired loan coverage ratio decreased to 16.6%Dividend proposal of EUR 0.19 per shareStrong confidence for outlook: 2024: EBIT guidance of EUR 67.5 million Mid-term 2026: net profit growth to EUR 30 million Helsinki, 28 March 2024 – Multitude SE, a listed European FinTech company, offering digital lending and online banking services to consumers, small and medium-sized businesses, and other FinTechs (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude”, “Company” or “Group”) announces that the Group's Annual Report, Corporate Governance Statement and Remuneration Report for the financial year ended 31 December 2023 have been

NOTICE TO CONVENE MULTITUDE SE’S ANNUAL GENERAL MEETING OF SHAREHOLDERS28.3.2024 18:30:00 CET | Press release

NOTICE TO CONVENE MULTITUDE SE’S ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is given to the shareholders of Multitude SE (Company) that the Annual General Meeting of the Company is to be held on 25 April 2024 at 10:00 a.m. (EEST / Finnish time) at the offices of Castrén & Snellman Attorneys Ltd, Eteläesplanadi 14, Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will start at 9:30 a.m. (EEST / Finnish time). Shareholders may also exercise their voting rights by voting in advance. Instructions concerning advance voting are provided in Section 3.4 of this notice. It will not be possible to participate in the meeting or follow the meeting via an online stream or otherwise in real time by the use of telecommunication connections or technical means. The meeting will be held in the English language. 1 MATTERS ON THE AGENDA OF THE GENERAL MEETING OF SHAREHOLDERS At the General Meeting of Shareholders, the following matte

Sword Group: NOTICE OF CONVOCATION TO THE SHAREHOLDERS FOR THE ANNUAL ORDINARY GENERAL MEETING OF THE COMPANY28.3.2024 18:00:00 CET | Press release

General Meeting on April 29, 2024, at 11:00 am at the registered office to deliberate on the following agenda: Under the authority of the General Meeting acting under the quorum and majority conditions of an Ordinary General Meeting: - Reading of the management report of the Board of Directors including the group management report and feedback on the conclusion of agreements referred to in article L.441-7 of the amended law of August 10, 1915, for the financial year ended December 31, 2023; - Reading of the report of the approved statutory auditor on the 2023 annual accounts, the group's consolidated financial statements, and on the execution of its mission; - Approval of the statutory accounts as of December 31, 2023; - Approval of the consolidated accounts as of December 31, 2023; - Allocation of the statutory exercise results as of December 31, 2023; - Discharge to the directors for their management for the financial year 2023; - Renewal of Mr. Jacques Mottard's director term; - Ren

HiddenA line styled icon from Orion Icon Library.Eye